Corbus Pharmaceuticals Holdings, Inc. Share Price
Stocks
CRBP
US21833P3010
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 11.08 USD | -3.32% |
|
+1.56% | +36.12% |
| 08-13 | Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating | MT |
| 08-07 | Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating | MT |
| Market Cap | 214M 184M 174M 158M 296M 20.23B 297M 2.05B 796M 10.38B 805M 787M 33.44B | P/E 2026 * |
-2.02x | P/E 2027 * | -1.93x |
|---|---|---|---|---|---|
| Enterprise Value | 214M 184M 174M 158M 296M 20.23B 297M 2.05B 796M 10.38B 805M 787M 33.44B | EV / Sales 2026 * |
193x | EV / Sales 2027 * | 89.3x |
| Free-Float |
98.8% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CRBP | Delayed | |
CBOE
| CRBP | Real-time | |
|
Boerse Muenchen
| 3371 | Real-time | |
|
Deutsche Boerse AG
| 3371 | Delayed | |
|
Tradegate
| 3371 | Real-time | |
|
Börse Stuttgart
| 3371 | Delayed |
Last Transcript : Corbus Pharmaceuticals Holdings, Inc.
| 1 day | -3.32% | ||
| 1 week | +1.56% | ||
| Current month | +1.56% | ||
| 1 month | +15.78% | ||
| 3 months | +46.56% | ||
| 6 months | +38.15% | ||
| Current year | +36.12% |
| 1 week | 10.39 |  | 11.6 |
| 1 month | 9.36 | | 11.6 |
| Current year | 7.12 | | 12.88 |
| 1 year | 7.12 | | 20.56 |
| 3 years | 3.03 | | 61.9 |
| 5 years | 2.11 | | 61.9 |
| 10 years | 2.11 | | 323.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 51 | 10/04/2014 |
Sean Moran
DFI | Director of Finance/CFO | 68 | 10/04/2014 |
Leonardo Nicacio
CTO | Chief Tech/Sci/R&D Officer | 48 | 05/07/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
BRD | Director/Board Member | 51 | 10/04/2014 |
John Jenkins
BRD | Director/Board Member | 68 | 04/06/2018 |
Rachelle Jacques
CHM | Chairman | 54 | 14/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/08/26 | Free | Chief Technology Officer | 250,009 | 1.3494% | ||
| 11/08/26 | Buy | Executive/Senior Manager | 2,600 | 0.0140% | ||
| 07/08/26 | Sell | Chief Financial Officer | -12,000 | 0.0648% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.32% | +1.56% | +12.37% | +64.64% | 214M | |
| -1.79% | -2.27% | +43.23% | +88.96% | 67.98B | |
| -2.06% | -0.18% | +39.67% | +86.44% | 64.94B | |
| -0.31% | +6.54% | -12.96% | +378.92% | 27.58B | |
| -3.00% | -2.90% | +33.13% | +12.54% | 25.74B | |
| +0.86% | +1.65% | -7.74% | -14.95% | 26.06B | |
| -1.46% | +0.42% | +23.61% | -18.61% | 20.09B | |
| -2.96% | -15.21% | +216.20% | +368.10% | 17.16B | |
| -1.49% | -4.88% | -6.60% | +531.89% | 14.92B | |
| -0.20% | +8.37% | +55.78% | +164.98% | 14.62B | |
| Average | -1.57% | +0.39% | +39.67% | +166.29% | 27.93B | |
| Weighted average by Cap. | -1.52% | +0.18% | +38.35% | +137.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.11M 956K 900K 822K 1.54M 105M 1.54M 10.63M 4.12M 53.82M 4.17M 4.08M 173M | 2.4M 2.07M 1.94M 1.77M 3.32M 227M 3.33M 22.96M 8.91M 116M 9.01M 8.82M 375M |
| Net income | -116M -100M -94.13M -85.99M -161M -10.98B -161M -1.11B -432M -5.63B -437M -427M -18.14B | -135M -116M -109M -99.96M -187M -12.76B -187M -1.29B -502M -6.55B -508M -496M -21.09B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | US$11.08 | -3.32% | 222,614 |
| 03/09/26 | US$11.46 | -0.17% | 475,360 |
| 02/09/26 | US$11.48 | +1.77% | 664,445 |
| 01/09/26 | US$11.28 | +3.39% | 901,296 |
| 31/08/26 | US$10.91 | 0.00% | 473,589 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRBP Stock
Select your edition
All financial news and data tailored to specific country editions
